Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Phase 2 trial of daily, oral polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia

Published:2012-07-03 Issue:2 Volume:119 Page:363-370
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Shanafelt Tait D.,Call Timothy G.,Zent Clive S.,Leis Jose F.,LaPlant Betsy,Bowen Deborah A.,Roos Michelle,Laumann Kristina,Ghosh Asish K.,Lesnick Connie,Lee Mao-Jung,Yang Chung S.,Jelinek Diane F.,Erlichman Charles,Kay Neil E.

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27719/fullpdf

Reference40 articles.

1. Tea polyphenols for health promotion;Khan;Life Sci.,2007

2. Tea and cancer;Yang;J Natl Cancer Inst.,1993

3. Possible protective effect of green tea intake on risk of adult leukaemia;Zhang;Br J Cancer.,2008

4. Dietary flavonoid intake and non-Hodgkin lymphoma risk;Frankenfeld;Am J Clin Nutr.,2008

5. A population-based, case-control study of green tea consumption and leukemia risk in southwestern Taiwan;Kuo;Cancer Causes Control.,2009

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of (−)-epigallocatechin gallate, a novel olfactory receptor 2AT4 agonist that regulates proliferation and apoptosis in leukemia cells;Heliyon;2024-05

2. Amelioration of Functional, Metabolic, and Morphological Deterioration in the Retina following Retinal Detachment by Green Tea Extract;Antioxidants;2024-02-15

3. Flavonoids as promising molecules in the cancer therapy: An insight;Current Research in Pharmacology and Drug Discovery;2024

4. Integrative Approaches in the Treatment of Patients Affected by Lymphoma;Current Oncology Reports;2023-12

5. Screening and Analysis of Skin Cancer Treatment Using Biocomponents of Plants Using Backpropagation Neural Networks: A Comprehensive Review;Current Cancer Therapy Reviews;2023-10-31